Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Ani Pharmaceuticals (ANIP) over the last 12 years, with Q3 2025 value amounting to $18.8 million.

  • Ani Pharmaceuticals' Deferred Taxes rose 43643.52% to $18.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.6 million, marking a year-over-year increase of 5562.1%. This contributed to the annual value of -$21.9 million for FY2024, which is 8665.25% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Deferred Taxes of $18.8 million as of Q3 2025, which was up 43643.52% from -$3.5 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Deferred Taxes high stood at $18.8 million for Q3 2025, and its period low was -$17.5 million during Q4 2024.
  • In the last 5 years, Ani Pharmaceuticals' Deferred Taxes had a median value of -$3.3 million in 2023 and averaged -$2.8 million.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Deferred Taxes crashed by 257526.88% in 2022, and later skyrocketed by 43643.52% in 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Deferred Taxes (Quarter) stood at -$8.1 million in 2021, then skyrocketed by 79.91% to -$1.6 million in 2022, then crashed by 413.6% to -$8.3 million in 2023, then crashed by 110.04% to -$17.5 million in 2024, then surged by 207.24% to $18.8 million in 2025.
  • Its Deferred Taxes was $18.8 million in Q3 2025, compared to -$3.5 million in Q2 2025 and -$3.4 million in Q1 2025.